Diagnostic value of plasma P‐tau217 in frontotemporal dementia spectrum disorders

Medientyp: E-Artikel
Titel: Diagnostic value of plasma P‐tau217 in frontotemporal dementia spectrum disorders
Beteiligte: Rojas, Julio C.; Vandevrede, Lawren; Heuer, Hilary W.; Toller, Gianina; Thijssen, Elisabeth H.; Proctor, Nicholas; Forsberg, Leah K.; Brushaber, Danielle; Ramos, Eliana Marisa; Coppola, Giovanni; Appleby, Brian; Bordelon, Yvette M.; Botha, Hugo; Dickerson, Brad C.; Dickson, Dennis W.; Domoto‐Reilly, Kimiko; Fagan, Anne M.; Fields, Julie A.; Fong, Jamie C.; Foroud, Tatiana M.; Galasko, Doug R.; Gavrilova, Ralitza H.; Geschwind, Daniel H.; Ghoshal, Nupur; [...]
Erschienen: Wiley, 2021
Erschienen in: Alzheimer's & Dementia
Sprache: Englisch
DOI: 10.1002/alz.055763
ISSN: 1552-5260; 1552-5279
Schlagwörter: Psychiatry and Mental health ; Cellular and Molecular Neuroscience ; Geriatrics and Gerontology ; Neurology (clinical) ; Developmental Neuroscience ; Health Policy ; Epidemiology
Entstehung:
Anmerkungen:
Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Frontotemporal dementia spectrum disorders (FTD) display complex neuropathological substrates and poor clinicopathological correlations, which hinders therapy development. Plasma P‐tau217 is an emerging tool to screen for Alzheimer’s disease (AD) pathology and may have diagnostic value in FTD.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>Plasma P‐tau217 was measured cross‐sectionally by electrochemiluminescence in FTD patients referred to ALLFTD from ARTFL (n = 628, 45.7% female, median age 66 ± 12 years). P‐tau217 differences by baseline phenotype, disease severity and genotype were determined with non‐parametric tests and general linear models. Associations between P‐tau217 and measures of disease severity and neuropsychological performance were determined with linear regressions corrected for age, sex, phenotype and <jats:italic>APOE</jats:italic>.</jats:p></jats:sec><jats:sec><jats:title>Result</jats:title><jats:p>The sample included 33% behavioral variant FTD, 23.6% primary progressive aphasia (PPA), 28.5% atypical parkinsonism, 1.6% amnestic dementia (AmDem), 2.8% FTD/motoneuron disease, 3% mild cognitive/behavioral impairment and 7.5% healthy controls. Only 1.6% carried FTD‐causing mutations. P‐tau217 was not related to age (r = 0.034, 95%CI ‐0.03 – 0.12, <jats:italic>p</jats:italic> = 0.4). Compared to controls (0.18 ± 0.07 pg/mL), P‐tau217 was elevated only in AmDem (0.58 ± 0.9 pg/mL, <jats:italic>p</jats:italic> = 0.001) and logopenic PPA (lvPPA, 0.71 ± 0.62 pg/mL <jats:italic>p</jats:italic> < 0.001). P‐tau217 ≥ 0.42 pg/mL effectively discriminated AmDem and lvPPA from all other phenotypes (AUC 0.87, 95%CI 0.77 – 0.96, <jats:italic>p</jats:italic> = 0.001, 77% sensitivity, 92% specificity). AmDem (60%) and lvPPA (91.7%) had the highest prevalence of high (≥ 0.42 pg/mL) P‐tau217, and the highest prevalence of <jats:italic>APOE4</jats:italic> (AmDem 40%, lvPPA 63.6%). <jats:italic>APOE4</jats:italic> carriers (0.23 ± 0.22 pg/mL) had higher P‐tau217, than non‐carriers (0.19 ± 0.09 pg/mL), regardless of phenotype (<jats:italic>APOE</jats:italic> effect <jats:italic>p</jats:italic> = .002, <jats:italic>APOE</jats:italic> x phenotype, <jats:italic>p</jats:italic> = 0.44). P‐tau217 was associated with worse clinical severity, mood, memory and executive function, but not with worse motor symptoms or social cognition.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>When FTD is suspected, high plasma P‐tau217 is strongly associated with amnestic dementia and logopenic PPA phenotypes. Pending completion of ongoing neuropathological, CSF and molecular neuroimaging analyses, the data support the use of plasma P‐tau217 to identify atypical AD as a cause or AD as a co‐pathology contributing to FTD clinical presentation.</jats:p></jats:sec>

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: